Greg Ambra
CEO

Greg Ambra has 20 years of experience in the clinical research industry, having held strategic leadership positions in industry leading sponsor and CRO companies. Serving as CEO of DZS Clinical Services since its acquisition by WDB Holdings in 2018, Ambra has continued to foster a culture of excellence, sense of urgency and a sincere desire to mentor and grow future leaders in the industry. As a result, Ambra has been involved in various strategic initiatives and drug and device development programs, many of which resulted in successful regulatory approvals and significant organizational improvement and growth.

Prior to assuming the role of CEO, Ambra led DZS Clinical Services as both President and Vice President of Clinical Operations from 2012 to 2018, after the niche CRO he founded (InQuiry Research), which provided data analytics and clinical development services to small and mid-size companies, was successfully sold to DZS Software Solutions, the developer of a proprietary clinical trials software. The acquisition led to the expansion of services to include full-service clinical development activities and clinical staffing. DZS Clinical Services has achieved consistent growth and expansion throughout his tenure and continues to grow the list of clients it serves.  As president, Ambra was part of the management team that executed the successful sale of their software platform at in 2017 and has improved top-line revenue within the CRO business ~400% over a four-year period.

Education
BA, History, Hofstra University, Hempstead, NY, Dean’s List, NCAA “Scholar/Athlete Award” (2002)
MA, Medical Sciences, Boston University, Boston, MA, Thesis Honors (1999)